Drug class

Asthma Therapy - Biologics/Monoclonal Antibodies

Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma. Read more about Asthma Therapy - Biologics/Monoclonal Antibodies

12 drugs in this class 7 manufacturers

Advertisement

Drugs in Asthma Therapy - Biologics/Monoclonal Antibodies

Showing 10–12 of 12 drugs

TEZSPIRE (tezepelumab-ekko)

ASTHMA THERAPY - THYMIC STROMAL LYMPHOPOIETIN INHIBITOR, MAB · CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ·+1
AMGEN
Filter & compare in the drug finder → Opens the drug finder with Asthma Therapy - Biologics/Monoclonal Antibodies preselected. Add indication or manufacturer filters there.

About Asthma Therapy - Biologics/Monoclonal Antibodies.

Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma.

Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic stromal lymphopoietin (anti-TSLP)—thereby halting key cascades driving chronic airway inflammation.

Their principal clinical role is to diminish exacerbations, enhance lung function, and reduce reliance on oral corticosteroids in severe eosinophilic or allergic asthma phenotypes.

Several agents within this class also extend therapeutically to overlapping type 2 inflammatory conditions, including chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and atopic dermatitis.